Valiant Laboratories Limited (VALIANTLAB.BO)
INR 127.0
(13.54%)
INR 127.0
(13.54%)
| Breakdown | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Operating Cash Flow | 18.07 Million | 560.51 Million | 22.51 Million | 91.09 Million |
| Net Income | 3.19 Million | 381.36 Million | 417.04 Million | 470.23 Million |
| Depreciation & Amortization | 19.65 Million | 15.63 Million | 24.9 Million | 26.07 Million |
| Deferred income taxes | - | - | - | - |
| Stock-based compensation | - | - | - | - |
| Change in working capital | -3.7 Million | 251.59 Million | -280.52 Million | -258.45 Million |
| Other non-cash items | -206.75 Million | -88.07 Million | -138.91 Million | -146.76 Million |
| Investing Cash Flow | -1.43 Billion | -551.68 Million | -122.38 Million | -166.69 Million |
| Investments in PPE | -458.7 Million | -376.81 Million | -68.76 Million | -16.69 Million |
| Acquisitions | - | -198.94 Million | 400 Thousand | - |
| Investment purchases | -980.06 Million | -336.17 Million | -4.02 Million | -150 Million |
| Sales/Maturities of investments | - | 199.2 Million | -400 Thousand | - |
| Other Investing Activities | -944.13 Million | 161.04 Million | -49.6 Million | -150 Million |
| Financing Cash Flow | 1.52 Billion | -9.34 Million | 61.81 Million | 114.3 Million |
| Debt repayment | -166.5 Million | -9.08 Million | -418.8 Million | -130.28 Million |
| Dividends payments | - | - | - | - |
| Common Stock Repurchased | - | - | - | - |
| Common Stock Issuance | 1.35 Billion | - | 488.68 Million | - |
| Other Financing Activities | -778 Thousand | -255 Thousand | -8.07 Million | 244.58 Million |
| Accounts receivables | 428.41 Million | 215.07 Million | -682.72 Million | -207.01 Million |
| Accounts payables | -213.69 Million | 80.23 Million | 353.35 Million | 14.43 Million |
| Inventory | 30.27 Million | 27.61 Million | -97.31 Million | -22.04 Million |
| Other working capital | -248.68 Million | -71.33 Million | 146.16 Million | -43.83 Million |
| Cash at beginning of period | 12.61 Million | 13.13 Million | 39.37 Million | 680 Thousand |
| Cash at end of period | 1.06 Billion | 12.62 Million | 1.31 Million | 39.37 Million |
| Capital Expenditure | -458.7 Million | -376.81 Million | -68.76 Million | -16.69 Million |
| Effect of forex changes on cash | - | - | - | -10 Thousand |
| Net cash flow / Change in cash | 1.04 Billion | -510 Thousand | -38.06 Million | 38.69 Million |
| Free Cash Flow | -440.62 Million | 183.7 Million | -46.25 Million | 74.4 Million |
| Breakdown | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 FY | 2021 FY |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 3.19 Million | -35.03 Million | 7.93 Million | 42.68 Million | 381.36 Million | 417.04 Million |
| Depreciation & Amortization | 19.65 Million | 4.94 Million | 4.9 Million | 4.61 Million | 15.63 Million | 24.9 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -3.7 Million | - | - | - | 251.59 Million | -280.52 Million |
| Other non-cash items | -206.75 Million | -4.94 Million | -4.9 Million | -4.61 Million | -88.07 Million | -138.91 Million |
| Investing Cash Flow | -1.43 Billion | - | - | - | -551.68 Million | -122.38 Million |
| Investments in PPE | -458.7 Million | - | - | - | -376.81 Million | -68.76 Million |
| Acquisitions | - | - | - | - | -198.94 Million | 400 Thousand |
| Investment purchases | -980.06 Million | - | - | - | -336.17 Million | -4.02 Million |
| Sales/Maturities of investments | - | - | - | - | 199.2 Million | -400 Thousand |
| Other Investing Activities | -944.13 Million | - | - | - | 161.04 Million | -49.6 Million |
| Financing Cash Flow | 1.52 Billion | - | - | - | -9.34 Million | 61.81 Million |
| Debt repayment | -166.5 Million | - | - | - | -9.08 Million | -418.8 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 1.35 Billion | - | - | - | - | 488.68 Million |
| Other Financing Activities | - | - | - | - | -255 Thousand | -8.07 Million |
| Accounts receivables | 428.41 Million | - | - | - | 215.07 Million | -682.72 Million |
| Accounts payables | -213.69 Million | - | - | - | 80.23 Million | 353.35 Million |
| Inventory | 30.27 Million | - | - | - | 27.61 Million | -97.31 Million |
| Other working capital | -248.68 Million | - | - | - | -71.33 Million | 146.16 Million |
| Cash at beginning of period | 12.61 Million | 1.62 Million | -6.31 Million | - | 13.13 Million | 39.37 Million |
| Cash at end of period | 1.06 Billion | -35.03 Million | 1.62 Million | 42.68 Million | 12.62 Million | 1.31 Million |
| Capital Expenditure | -458.7 Million | - | - | - | -376.81 Million | -68.76 Million |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 1.04 Billion | -36.65 Million | 7.93 Million | 42.68 Million | -510 Thousand | -38.06 Million |
| Free Cash Flow | -440.62 Million | -35.03 Million | 7.93 Million | 42.68 Million | 183.7 Million | -46.25 Million |
DEF
NCX
FGR
PRIZ
0ROG
INDP